Seòmar agus comataidhean

The Scottish Government have allocated £1 million to support local authorities to date to cover the costs of welcome activities, such as access to meals, translation services and trauma support. We recognise that costs arising may go beyond the £1 million initially made available, and we are working with COSLA and local authorities to ensure that reasonable costs associated with the super sponsor scheme are met by the Scottish Government. The full costs are yet to be determined.

The number of C-peptide tests taken by people with type 1 diabetes since 1 November 2021 can be found in the following table. The information on the number of c-peptide tests being offered to those with type 1 diabetes is not held centrally.

No data is collected on the return or disposal of medicines due to the difficult nature of quantifying and recording this information. Health Boards are responsible for ensuring unused medicines are safely disposed of, though are not required to record this data.

The Scottish Government continues to closely monitor the outcomes of further research to ensure that any decisions to make Evusheld ® available to patients in Scotland in the future are based on the best available evidence. The RAPID C-19 group is a collaborative UK-wide partnership between the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and others. To date, the RAPID C-19 group and the COVID-19 UK expert panel have both considered a full range of evidence, including clinical trial data, in vitro (in the laboratory) analysis and observational studies and have advised that there is insufficient evidence available at this time to support the procurement and deployment of Evusheld ® .

The RAPID C-19 group is keeping this position under active review, including through monitoring any emerging data. Building on the work of the RAPID C-19 group, the SMC is exploring the potential for collaboration with NICE on a single technology assessment (STA) of tixagevimab–cilgavimab (Evusheld ® ) for the prevention of COVID-19. In order to gain further evidence, consideration is also being given to establishing a clinical trial as a route to answering outstanding questions on the link between in vitro tests and clinical outcomes for current and future variants, which is currently not known. The trial may also assist with evaluating the effectiveness and safety of a higher dose of 600mg, which is now being used in a number of countries, which have previously purchased Evusheld®, as this was not tested in the company’s randomised controlled trials.

I have recently written to the UK Government supporting the establishment of a clinical trial and stating my wish to see individuals in Scotland included.

The information requested is not held centrally.

We expect all NHS Boards to have robust governance arrangements in place, including those for risk assessment and business continuity; as informed by, and consistent with, national policies and frameworks. NHS Lanarkshire has confirmed that, as part of their routine winter planning work, they have been engaging with local planning partners to ensure all eventualities are carefully considered.

An estimate of the number of people with complex disabilities was published by the charity Sense in a short report in May 2022, which estimated that there were around 157,000 people in Scotland that could have complex disabilities, where complex disabilities were defined as a person having two or more of the following conditions: ‘deaf or hearing impairment’, ‘blind or vision impairment’, ‘learning disability’, ‘autism’. A link to the report is available here: https://www.sense.org.uk/about-us/statistics/complex-disabilities-in-scotland/

The decision not to procure Evusheld ® at this time has been taken based on clinical advice, rather cost.

The RAPID C-19 group is a collaborative UK-wide partnership between the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and others. To date, the RAPID C-19 group and the COVID-19 UK expert panel have both considered a full range of evidence, including clinical trial data, in vitro (in the laboratory) analysis and observational studies and have advised that there is insufficient evidence available at this time to support the procurement and deployment of Evusheld ® .

The Scottish Government continues to closely monitor the outcome of further research to ensure that any decisions to make Evusheld ® available to patients in Scotland in the future are based on the best available evidence.

I refer the member to the answer to question S6W-11806 on 15 November 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers .

We are developing a new 10 year cancer strategy to launch in Spring 2023, which will take a comprehensive approach to improving patient pathways from prevention and diagnosis through to treatment and post-treatment care.

Blood cancer charities have been engaged throughout the development of the cancer strategy including responding to the public consultation (to which there were a total of over 250 responses) and in further meetings with the Third Sector.